Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 29, Issue 4, 2009, Pages 372-377

  Leuchter, Andrew F ^a,b   McCracken, James T ^b   Hunter, Aimee M ^a,b   Cook, Ian A ^a,b   Alpert, Jonathan E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Catechol O methyltransferase (COMT); Dopamine; Genetic polymorphisms; Major depressive disorder; Monoamine oxidase A (MAO A); Norepinephrine; Placebo response

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; FLUOXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; GENE FUNCTION; GENETIC CODE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PLACEBO EFFECT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; PHENOTYPE; PLACEBO EFFECT; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68449085750     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181ac4aaf     Document Type: Article

References (40)

1. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565-590.
2. Klosterhalfen S, Enck P. Neurophysiology and psychobiology of the placebo response. Curr Opin Psychiatry. 2008;21:189-195.
3. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. JPsychiatr Res. 2008;42:791-796.
4. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry. 2004;56:67-71.
5. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80:1-27.
6. Petrovic P, Kalso E, Petersson KM, et al. Placebo and opioid analgesia-imaging a shared neuronal network. Science. 2002;295:1737-1740.
7. Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159:728-737.
8. de la Fuente-Fernandez R, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci. 2002;25:302-306.
9. Mingote S, de Bruin JP, Feenstra MG. Noradrenaline and dopamine efflux in the prefrontal cortex in relation to appetitive classical conditioning. J Neurosci. 2004;24:2475-2480.
10. Ventura R, Cabib S, Alcaro A, et al. Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release. J Neurosci. 2003;23:1879-1885.
11. Ventura R, Alcaro A, Puglisi-Allegra S. Prefrontal cortical norepinephrine release is critical for morphine-induced reward, reinstatement and dopamine release in the nucleus accumbens. Cereb Cortex. 2005;15:1877-1886.
12. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403-450.
13. Aston-Jones G, Cohen JD. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J Comp Neurol. 2005;493:99-110.
14. Rossetti ZL, Carboni S. Noradrenaline and dopamine elevations in the rat prefrontal cortex in spatial working memory. J Neurosci. 2005;25:2322-2329.
15. Mickey BJ, Ducci F, Hodgkinson CA. Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J Neurosci. 2008;44:11354-11359.
16. Schultz W. Reward signaling by dopamine neurons. Neuroscientist. 2001;7:293-302.
17. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev. 2003;42:33-84.
18. Harley CW. Norepinephrine and dopamine as learning signals. Neural Plast. 2004;11:191-204.
19. Benedetti F, Colloca L, Torre E, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci. 2004;7:587-588.
20. Oreland L, Engberg G. Relation between brain monoamine oxidase (MAO) activity and the firing rate of locus coeruleus neurons. Naunyn Schmiedebergs Arch Pharmacol. 1986;333:235-239.
21. Bilder RM, Volavka J, Lachman HM, et al. The catechol-O-methyltransf erase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29:1943-1961.
22. Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet. 1991;49:383-392.
23. Jansson M, McCarthy S, Sullivan PF, et al. MAOA haplotypes associated with thrombocyte-MAO activity. BMC Genet. 2005;6:46.
24. Buckholtz JW, Callicott JH, Kolachana B, et al. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol Psychiatry. 2008;13:313-324.
25. Lachman HM, Morrow B, Shprintzen R, et al. Association of codon 108/158 catechol-0-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet. 1996;67:468-472.
26. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen. New York: Biometrics Research, New York State Psychiatric Institute; 2002.
27. Leuchter AF, Cook IA, Witte EA, et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002;159:122-129.
28. Hunter AM, Ravikumar S, Cook IA, et al. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression. Acta Psychiatr Scand. 2008;119(4):266-273.
29. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O- methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243-250.
30. Tadic A, Muller MJ, Rujescu D, et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B:325-331.
31. Hasler G, Drevets WC, Manji HK, et al. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29:1765-1781.
32. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64:327-337.
33. Peters EJ, Slager SL, McGrath PJ, et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry. 2004;9:879-889.
34. Gutierrez B, Arias B, Gastó C, et al. Association analysis between a functional polymorphism in the monoamine oxidase A gene promoter and severe mood disorders. Psychiatr Genet. 2004;14:203-208.
35. Yu YW, Tsai SJ, Hong CJ, et al. Association study of a monoamine oxidase A gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology. 2005;30:1719-1723.
36. Buckholtz JW, Meyer-Lindenberg A. MAOA and the neurogenetic architecture of human aggression. Trends Neurosci. 2008;31:120-129.
37. Zubieta JK, Bueller JA, Jackson LR, et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci. 2005;25:7754-7762.
38. Brody AL, Mandelkern MA, Olmstead RE, et al. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry. 2006;63:808-816.
39. Villegier AS, Salomon L, Granon S, et al. Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine. Neuropsychopharmacology. 2006;31:1704-1713.
40. Jin Y, Chen D, Hu Y, et al. Association between monoamine oxidase gene polymorphisms and smoking behaviour in Chinese males. Int J Neuropsychopharmacol. 2006;9:557-564.